ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Eris Lifesciences Limited conducted its 20th Annual General Meeting on September 25, 2026. Shareholders transacted business including the adoption of audited financial statements and director re-appointments.
Eris Lifesciences allotted 1,55,264 equity shares upon the exercise of employee stock options under its ESOP-2021 scheme.
Eris Lifesciences appointed Mr. Akhil Awasthi as Non-Executive Independent Director effective September 26, 2026 for a five-year term, subject to shareholder approval. No monetary value is associated with the appointment.
Mr. Krishnakumar Vaidyanathan has resigned as Executive Director and Chief Operating Officer of Eris Lifesciences Limited, effective September 30, 2026.
Eris Lifesciences issued a clarification regarding media reports about its loan amount. It advised investors to rely only on the company's official exchange disclosures.
Eris Lifesciences has entered into a term loan agreement with Axis Bank Limited for ₹45 Crore to meet general liabilities.
Eris Lifesciences has released its Annual Report for the financial year 2025-26, including the notice for the 20th Annual General Meeting.
Eris Lifesciences will hold its Twentieth Annual General Meeting on September 25, 2026, through video conferencing to transact ordinary and special business.
Eris Lifesciences Limited's board approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director. The company also scheduled its 20th Annual General Meeting for September 25, 2026.
Eris Lifesciences Limited has drawn down a ₹64.40 Crore working capital term loan from Axis Bank. The funds will be used to meet existing short-term liabilities.
Eris Lifesciences Q1 FY27 showed 13% revenue growth, but shifting product mix toward lower-margin biologics and insulin is compressing gross margins. Management remains optimistic about GLP-1 uptake despite slow initial patient adoption.
Eris Lifesciences Limited allotted 4,816 equity shares under its ESOP-2017 scheme. This allotment increases the company's total paid-up share capital to Rs. 13,85,83,305.
Eris reports steady 14% domestic growth but faces a gross margin contraction due to a higher mix of lower-margin biologics and insulin products.
Eris reports 13% YoY revenue growth in Q1 FY27, reaching ₹873 Cr, driven by a 14% increase in Domestic Branded Formulations (DBF) and strategic expansion into biologics and insulins.
Eris Lifesciences Ltd reported revenue from operations of ₹873.2 Cr (+13.0% YoY) and net profit of ₹143.3 Cr (+14.5% YoY) for Q1 FY27.
Eris Lifesciences has scheduled a Board Meeting for July 29, 2026. The board will consider and approve financial results for the quarter ended June 30, 2026.
Eris Lifesciences filed its quarterly shareholding pattern for the period ending June 30, 2026. No major promoter changes or material financial events reported.
Eris Lifesciences allotted 11,233 equity shares under its ESOP scheme. Total paid-up share capital increased to 138,578,489 shares following the allotment.
Eris Lifesciences allotted 11,233 equity shares under the ESOP-2021 scheme. The total value of the allotment is approximately ₹0.68 Crore.
Eris Lifesciences allotted 11,233 equity shares under the ESOP-2021 scheme. The total value of the allotment is approximately ₹0.68 Crore.
Eris reports FY26 revenue of INR 3,129 cr with 36% EBITDA margin. Strategy focused on high-value therapies (80% revenue) and aggressive M&A integration.
Eris Lifesciences paid ₹109.12 Crore in gross interest for two NCD series. This routine debt servicing confirms the company's ability to meet its ongoing financial obligations.
Eris Lifesciences Limited paid a ₹0.08 Crore total penalty to BSE and NSE for board non-compliance. The company confirmed the vacancy was filled on March 14, 2026.
Eris Lifesciences filed its FY2026 Secretarial Compliance Report, noting a Rs. 0.13 Crore fine for delayed director appointment. The company has since achieved full compliance.
Eris Lifesciences Q3 FY26 results show a 10% YoY revenue increase, led by aggressive insulin market share gains, while discontinuing non-core brands to optimize margins.
Eris Lifesciences announced postal ballot results confirming Mr. Vineet Varma’s appointment as an Independent Director. Shareholders approved the resolution with a 99.92% majority.
Eris delivered record Q3 revenue but faces near-term margin pressure from new launch investments and non-core portfolio pruning.
Eris Lifesciences declared an interim dividend of ₹7.21 per share for FY 2026-27. The record date is May 29, with payment scheduled by June 19.
Eris reports FY26 revenue of ₹3,129 cr (up 8.1% yoy) with 35.8% EBITDA margin. Strategy focuses on Gx Semaglutide leadership and scaling international CDMO business.
Eris Lifesciences Ltd reported revenue from operations of ₹756.6 Cr (+7.3% YoY) and net profit of ₹279.1 Cr (+172.8% YoY) for Q4 FY26.